VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay

Article Related Press Releases (1) Related Articles (5) Related SEC Filings (1) Stock Quotes (1) Comments (0)

VIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.

The following are a few key pieces from VIVUS conference call:

• 3,504 patients are on Qsymia to date;
  
• Average price for 1-month supply is $160, with 20 percent reimbursement coverage since launch; and
  
• About 30 percent of Qsymia prescriptions are abandoned due to cash outlay.

VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Lazard Capital Downgrades Vivus (VVUS) to Neutral
• UPDATE: Solarcity (SCTY) Posts Q1 GAAP Loss of 41c/Share
• BlackBerry's (BBRY) BBM to go accross multiple platforms this summer

Create E-mail Alert Related Categories

Conference Calls

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?